Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cardiff Oncology ( (CRDF) ) has provided an update.
On January 27, 2026, Cardiff Oncology announced a major executive leadership transition as it prepares to move its lead cancer therapy, onvansertib, toward late-stage clinical development. Board member and experienced biotech executive Mani Mohindru, PhD, was appointed interim Chief Executive Officer, while CEO Mark Erlander, PhD, and CFO James Levine stepped down from their roles; the company also promoted long-time finance executive Brigitte Lindsay to Chief Accounting Officer and launched a search for permanent CEO and CFO successors. Management and board statements framed these changes as aligning Cardiff’s executive and financial leadership with the demands of advancing onvansertib in first-line RAS‑mutated metastatic colorectal cancer and broadening its potential across other difficult‑to‑treat cancers, signaling an intensified focus on execution, clinical progress and strategic positioning at a pivotal stage in the company’s development.
The most recent analyst rating on (CRDF) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.
Spark’s Take on CRDF Stock
According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and significant cash burn), partially offset by low leverage. Technical indicators are modestly supportive in the near term (positive MACD; price above shorter-term averages), but the stock remains below its 200-day average. Valuation provides limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on CRDF stock, click here.
More about Cardiff Oncology
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on advancing innovative cancer treatments through PLK1 inhibition, a validated oncology target. Its lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor in mid-stage (Phase 2) clinical development for first-line treatment of RAS-mutated metastatic colorectal cancer, a large and underserved patient population, and is also being studied in other PLK1-driven solid tumors and hematologic malignancies, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia.
Average Trading Volume: 874,335
Technical Sentiment Signal: Buy
Current Market Cap: $198M
See more insights into CRDF stock on TipRanks’ Stock Analysis page.